<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01710267</url>
  </required_header>
  <id_info>
    <org_study_id>12041</org_study_id>
    <nct_id>NCT01710267</nct_id>
  </id_info>
  <brief_title>Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)</brief_title>
  <acronym>RivaMoS2</acronym>
  <official_title>Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Dr. med. Walter A. Wuillemin, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research Foundation, Division of Hematology, Luzerner Kantonsspital, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer (Schweiz) AG, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Luzerner Kantonsspital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rivaroxaban (RXA; brand name Xarelto®) is an oral direct factor Xa inhibitor that is applied
      for prophylaxis of venous thromboembolism after major orthopedic surgery. Additionally, RXA
      is approved by Swissmedic to be used at a therapeutic dose for primary therapy of VTE and for
      prophylaxis of cerebrovascular events in non-valvular atrial fibrillation.

      This is an explorative laboratory study to evaluate the intra-individual variability of RXA
      conc. in time and to standardize assays among 9 Swiss laboratories to determine RXA conc.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rivaroxaban (RXA; brand name Xarelto®) is an oral direct factor Xa inhibitor that is applied
      for prophylaxis of venous thromboembolism (VTE) after major orthopedic surgery of the lower
      limbs such as hip and knee replacement surgery. Additionally, RXA is approved by Swissmedic
      to be used at a therapeutic dose for primary therapy of VTE and for prophylaxis of
      cerebrovascular events in non-valvular atrial fibrillation.

      Monitoring of RXA concentration (conc.) is generally not required because of its stable
      pharmacokinetic and pharmacodynamic profile, even in patients with renal insufficiency.
      However, there are several clinical situations, in which it may be desirable to measure the
      RXA plasma conc. The range of RXA conc. is wide among individuals with typical peak levels of
      median 244 µg/L (IQR 175-360) and trough levels of median 32 µg/L (IQR 19-60) with once daily
      doses of 20 mg RXA.

      This is an explorative laboratory study to evaluate the intra-individual variability of RXA
      conc. in time and to standardize assays among 9 Swiss laboratories to determine RXA conc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the effect of RXA on trough and peak RXA conc. values in time</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of RXA on coagulation assays in time</measure>
    <time_frame>14 days</time_frame>
    <description>coagulation assays such as PT, PTT, individual coagulation factors, PiCT, ROTEM, multiplate</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Observation group</arm_group_label>
    <description>This group includes all volunteers of this observation study.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples for coagulation assays
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy male volunteers aged 18-65 years
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male, aged 18-65 years

          -  No known comorbidity or disease

          -  No known galactose intolerance, lactase deficiency or glucose galactose malabsorption

          -  Taking no other medicaments

          -  No history for disorders regarding hemostasis

          -  Initial screening laboratory test showing normal values for liver/pancreas function
             (ALAT,ASAT,gGT, alkalic phosphatase, bilirubin, amylase, lipase), kidney function
             (creatinine), hematogram (white blood cell count, hemoglobin, platelet count), and
             coagulation parameters (&quot;Gerinnungsstatus&quot; with PT, aPTT, fibrinogen, thrombin time)

          -  written informed consent

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter A Wuillemin, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Luzerner Kantonsspital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <state>LU</state>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://www.luks.ch/standorte/luzern/kliniken/medizin/haematologie.html</url>
    <description>Division of Hematology and Central Hematology Laboratory, Luzerner Kantonsspital, Switzerland</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2012</study_first_submitted>
  <study_first_submitted_qc>October 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2012</study_first_posted>
  <last_update_submitted>March 31, 2015</last_update_submitted>
  <last_update_submitted_qc>March 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Luzerner Kantonsspital</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Dr. med. Walter A. Wuillemin, MD, PhD</investigator_full_name>
    <investigator_title>Chief, Division of Hematology and Central Hematology Laboratory, Luzerner Kantonsspital, Switzerland</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

